Clinical trials: Infections, Streptococcal
Rheumatic Heart Disease, Rheumatic Heart Disease in Children
Clinical Trial Phase I/IIa to Evaluate the Safety and Immunogenicity of StreptInCor
This is a Phase I/IIa, randomized, double-blind, placebo-controlled, dose-escalation clinical trial to test the candidate vaccine StreptInCor.
- Conditions
- Rheumatic Heart Disease, Rheumatic Heart Disease in Children, Vaccine Adverse Reaction, Rheumatic Diseases
- Trial name
- StreptInCorVac (NCT07078357)
- Testing
- StrepIncor
- Where
- Brazil
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Pneumococcal Disease
Nasopharyngeal Carriage Study in Healthy Kenyan Toddlers
This study evaluated the change in nasopharyngeal carriage (NPC) of Streptococcus pneumoniae (SPn), hypothesizing that it would be reduced post-vaccination with Streptococcus pneumoniae whole cell vaccine with aluminum hydroxide…
- Trial name
- NCT02146365
- Where
- Kenya
- Volunteers
- 297 people, healthy volunteers welcome
- Sponsor
- PATH
Group A Streptococcal Infection
A Trial of a Peptide-based Group A Streptococcal (GAS) Vaccine Candidate in Healthy Individuals.
The purpose of this study is to investigate the safety and antibody (germ fighters) response of experimental (investigational) vaccine candidates against the germ group A streptococcus when injected into the arm of healthy adults.
- Trial name
- NCT04882514
- Testing
- p*17-K4S2, J8-K4S2, Rabavert vaccine
- Where
- Canada
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Alberta
Pneumonia, Pneumococcal
Immunogenicity and Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Healthy Volunteers Aged 2 Years and Above
The purpose of this study is to evaluate Immunogenicity and safety of 23-Valent Pneumococcal Polysaccharide Vaccine in healthy volunteers aged 2 Years and above.
- Trial name
- NCT04278248
- Testing
- 23-Valent Pneumococcal Polysaccharide Vaccine
- Where
- China
- Volunteers
- 1,940 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Pneumococcal Disease, COVID-19
Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2
Study of the safety and immunogenicity of 20vPnC and a booster dose of BNT162b2 administered at the same visit or each vaccine given alone
- Conditions
- Pneumococcal Disease, COVID-19, SARS-CoV-2 Infection
- Trial name
- NCT04887948
- Testing
- 20-valent pneumococcal conjugate vaccine (20vPnC), BNT162b2, Saline
- Where
- 27 sites in United States
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Pfizer
Periodontal Diseases, Dental Plaque
Oral Health Literacy Tailored Communication
The purpose of this study to investigate attitude, oral health literacy and psychological factors in order to evaluate if these factors are important for oral health in adults.
- Conditions
- Periodontal Diseases, Dental Plaque, Dental Calculus, Sialorrhea
- Trial name
- NCT01118143
- Testing
- Tailored oral health literacy instruction
- Where
- 2 sites in Norway
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- University of Tromso
Ankylosing Spondylitis, Rheumatic Arthritis
Biomarkers in Inflammatory Rheumatic Diseases Diagnosis
Ankylosing spondylitis (AS), Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) are three diseases where early diagnosis remains a major challenge.
- Conditions
- Ankylosing Spondylitis, Rheumatic Arthritis, Systemic Lupus Erythematosus
- Trial name
- BIRDD (NCT06778343)
- Where
- Portugal
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Universidade Nova de Lisboa
Pneumococcal Infectious Disease
Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine
A Phase Ⅲ clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13) developed by Sinovac Life Science Co., Ltd will be conducted in pediatric population aged 2 months (minimum 6 weeks)-5 years (before 6th birthday).
- Trial name
- NCT06617715
- Testing
- Sinovac PCV13, Prevnar®
- Where
- China
- Volunteers
- 3,080 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Mycobacterium Avium-intracellulare Infection, HIV Infections
Effects of MAC Preventive Therapy on Disease-Causing Bacteria in HIV-Infected Patients: A Substudy of CPCRA 048
Some people who have taken azithromycin to prevent MAC (Mycobacterium avium Complex, a bacterial infection common in HIV-infected persons) have been found to carry antibiotic-resistant bacteria (germs that grow despite the…
- Conditions
- Mycobacterium Avium-intracellulare Infection, HIV Infections, Pneumococcal Infections
- Trial name
- NCT00000933
- Where
- 15 sites in United States
- Volunteers
- 326 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Skin Infections, Bacterial
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
The purpose of this study is to provide further evidence of the clinical and bacteriological efficacy of retapamulin in the treatment of subjects with SITL or impetigo due to MRSA.
- Trial name
- NCT00852540
- Testing
- Retpamulin Ointment, 1%, Linezolid
- Where
- 53 sites in United States
- Volunteers
- 410 people
- Sponsor
- Stiefel, a GSK Company
Pneumococcal Disease
A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults
The purpose of this clinical trial is to learn about a pneumococcal vaccine with a new ingredient (PF-07872411) intended to enhance the effects of the vaccine.
- Trial name
- NCT05831124
- Testing
- Low dose multivalent pneumococcal conjugate vaccine formulation A, Low dose multivalent pneumococcal conjugate vaccine formulation B, Low dose of multivalent pneumococcal conjugate vaccine control
- Where
- 9 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumonia, Pneumococcal, Pneumococcal Infections
Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults
The purpose of this study is to assess the efficacy of 13-valent pneumococcal conjugate vaccine in the prevention of the first episode of vaccine-type pneumococcal community-acquired pneumonia in adults.
- Conditions
- Pneumonia, Pneumococcal, Pneumococcal Infections, 13-valent Pneumococcal Vaccine
- Trial name
- CAPITA (NCT00744263)
- Testing
- VACCINE: 13-valent pneumococcal conjugate vaccine
- Where
- 159 sites in Netherlands
- Volunteers
- 84,496 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Infections
Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants
This is a Phase 2, randomized, active-controlled, open-label study with a 3-arm parallel design. Healthy 2-month old infants (42 to 98 days of age) with no history of pneumococcal vaccination will be randomized in a 1:1:1 ratio…
- Trial name
- NCT03550313
- Testing
- Multivalent, Prevnar 13
- Where
- 48 sites in United States
- Volunteers
- 565 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Infection
A Study to Evaluate the Safety and Immunogeneicity of Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults
phase-1 study pneumococcal conjugate vaccine study in healthy adults
- Trial name
- NCT03549208
- Testing
- LBVE01, LBVE02, Prevnar13
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- LG Chem
Group B Streptococcal Infection
Effect of Probiotics on GBS Colonization Status During Pregnancy: A Pilot Randomized Controlled Trial
Group B Streptococcus (GBS) is the leading cause of neonatal morbidity and mortality in Canada. It may be passed from a study participant colonized in the genital tract by GBS to their baby during vaginal birth.
- Trial name
- NCT02528981
- Testing
- Probiotic
- Where
- Canada
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Toronto Metropolitan University
Rheumatic Heart Disease, Heart Diseases
Mobile Health in Structural Heart Disease
The primary objective of this investigation was to assess the impact of new mobile health devices on health outcomes among patients with rheumatic and structural heart disease in a resource limited area.
- Trial name
- ASEF-VALUES (NCT02881398)
- Testing
- mHealth, Standard-Care
- Volunteers
- 253 people
- Sponsor
- Sri Sathya Sai Institute of Higher Medical Sciences
Rheumatic Heart Disease in Children
School-based Program for the Prevention of Rheumatic Heart Disease in Endemic Regions
The overall objective of the PREVENT trial is to evaluate the effectiveness of an integrated, school-based program for the prevention of rheumatic heart disease (RHD) in regions with an endemic pattern of RHD.
- Trial name
- PREVENT (NCT06720272)
- Testing
- School nurse program
- Where
- 2 sites in Nepal, Zambia
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Thomas Pilgrim
Pharyngitis, Streptococcus Pyogenes Infection
An Assessment of Rapid Streptococcal Tests in Community Clinics in Israel
There is a large over-use of antibiotics in family medicine, especially in upper respiratory tract infections. This study is designed to determine if the use of rapid Streptococcal tests in primary care clinics can lower the rate…
- Conditions
- Pharyngitis, Streptococcus Pyogenes Infection, Streptococcus Pyogenes Identification
- Trial name
- NCT00535093
- Testing
- rapid streptococcal testing
- Where
- Israel
- Volunteers
- 7,000 people
- Sponsor
- Meir Medical Center
Pneumococcal Disease
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan
A phase 3, randomized, double-blind trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults 60 years of age and older in Japan, Korea, and Taiwan
- Trial name
- NCT04875533
- Testing
- 20vPnC, Saline, 13vPnC
- Where
- 28 sites in Japan, South Korea and 1 more
- Volunteers
- 1,425 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Disease
Safety and Immunogenicity of the 'EuPCV15' in Healthy Korean Adults
The safety and immunogenicity of EuPCV15 compared to Prevenar13 are assessed in healthy adults.
- Trial name
- NCT04830358
- Testing
- EuPCV15, Prevenar13
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- EuBiologics Co.,Ltd